4.8 Article

Recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poroma and porocarcinoma

期刊

JOURNAL OF CLINICAL INVESTIGATION
卷 129, 期 9, 页码 3827-3832

出版社

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI126185

关键词

-

资金

  1. National Cancer Center Research and Development Fund [29-E-5]
  2. Japan Society for the Promotion of Science KAKENHI [16H04701]
  3. Grants-in-Aid for Scientific Research [16H04701] Funding Source: KAKEN

向作者/读者索取更多资源

Poroma is a benign skin tumor exhibiting terminal sweat gland duct differentiation. The present study aimed to explore the potential role of gene fusions in the tumorigenesis of poromas. RNA sequencing and reverse transcription PCR identified highly recurrent YAP1-MAML2 and YAP1-NUTM1 fusions in poromas (92/104 lesions, 88.5%) and their rare malignant counterpart, porocarcinomas (7/11 lesions, 63.6%). A WWTR1-NUTM1 fusion was identified in a single lesion of poroma. Fluorescence in situ hybridization confirmed genomic rearrangements involving these genetic loci. Immunohistochemical staining could readily identify the YAP1 fusion products as nuclear expression of the N-terminal portion of YAP1 with a lack of the C-terminal portion. YAP1 and WWTR1, also known as YAP and TAZ, respectively, encode paralogous transcriptional activators of TEAD, which are negatively regulated by the Hippo signaling pathway. The YAP1 and WWTR1 fusions strongly transactivated a TEAD reporter and promoted anchorage-independent growth, confirming their tumorigenic roles. Our results demonstrate the frequent presence of transforming YAP1 fusions in poromas and porocarcinomas and suggest YAP1/TEAD-dependent transcription as a candidate therapeutic target against porocarcinoma.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Central nervous system sarcoma with ATXN1::DUX4 fusion expands the concept of CIC-rearranged sarcoma

Kaishi Satomi, Makoto Ohno, Takashi Kubo, Mai Honda-Kitahara, Yuko Matsushita, Koichi Ichimura, Yoshitaka Narita, Hitoshi Ichikawa, Akihiko Yoshida

Summary: ATXN1::DUX4 is a recurrent alternative molecular event in sarcoma type defined by CIC rearrangement, sharing similar phenotype and DNA methylation profile, suggesting an expansion of tumor concept.

GENES CHROMOSOMES & CANCER (2022)

Article Biochemistry & Molecular Biology

ARHGAP-RhoA signaling provokes homotypic adhesion-triggered cell death of metastasized diffuse-type gastric cancer

Masayuki Komatsu, Hitoshi Ichikawa, Fumiko Chiwaki, Hiromi Sakamoto, Rie Komatsuzaki, Makoto Asaumi, Kazuhisa Tsunoyama, Takeo Fukagawa, Hiromichi Matsushita, Narikazu Boku, Keisuke Matsusaki, Fumitaka Takeshita, Teruhiko Yoshida, Hiroki Sasaki

Summary: Frequent gene fusions of ARHGAP6/ARHGAP26 are found in peritoneally-metastasized gastric and pancreatic cancer, leading to downregulation of RhoA-ROCK-MLC2 signaling and cell death. The findings suggest the tumor-suppressive nature of ARHGAP-RhoA signaling and may provide a new avenue for drug discovery against this refractory cancer.

ONCOGENE (2022)

Article Oncology

IDH-negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site-A diagnostic pitfall

Tetsuya Sekita, Akihiko Yoshida, Akira Kawai, Hitoshi Ichikawa, Eisuke Kobayashi

Summary: Dedifferentiated chondrosarcoma is a rare subtype of sarcoma that presents diagnostic challenges and can be easily confused with other diseases. This study used genomic analysis to determine the origin of the lesions and provided a diagnostic method for dedifferentiated chondrosarcoma lacking specific gene mutations.

GENES CHROMOSOMES & CANCER (2023)

Article Oncology

Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study

Takafumi Koyama, Toshio Shimizu, Yuki Kojima, Kazuki Sudo, Hitomi Sumiyoshi Okuma, Tatsunori Shimoi, Hitoshi Ichikawa, Shinji Kohsaka, Ryo Sadachi, Akihiro Hirakawa, Akihiko Yoshida, Reiko Makihara Ando, Toshihide Ueno, Mitsuru Yanagaki, Naoko Matsui, Kenichi Nakamura, Noboru Yamamoto, Kan Yonemori

Summary: Intimal sarcoma is a rare and life-threatening cancer, with most cases exhibiting MDM2 amplification. This study found that the MDM2 inhibitor, Milademetan, showed potential clinical benefits in patients with MDM2-amplified intimal sarcoma. The use of biomarkers such as TWIST1 amplification and CDKN2A loss, as well as sequential liquid biopsy of TP53, could help optimize treatment outcomes.

CANCER DISCOVERY (2023)

暂无数据